The continuing spread of COVID-19 has raised the importance of rapid screening. CareStart Covid-19 Antigen Home Test Kit in new Zealand Demand for rapid test kits is rising because, unlike polymerase chain reaction (PCR) tests, they require no special equipment. Access Bio, Inc., the world's leading manufacturer of rapid test kits for malaria, developed CareStart COVID-19 Ag to rapidly detect antigens of SARS-CoV-2, the virus which causes COVID-19.
This product is available under FDA/EUA authorization.
CareStart Covid-19 Antigen Home Test Kit in new Zealand
Rapid results in 10 minutes
Minimally invasive specimen collection (nasopharyngeal or anterior nasal)
Intended at POC setting (i.e., inpatient care settings) by medical professionals
For in-vitro use only
Detect SARS-CoV-2 nucleocapsid protein antigen
For prescription use only
Anterior nasal swab (Shallow swab)
The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers.